Erasca, Inc. (NASDAQ:ERAS – Get Free Report)’s stock price hit a new 52-week high on Friday . The stock traded as high as $3.38 and last traded at $3.36, with a volume of 54846 shares traded. The stock had previously closed at $3.27.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the company. HC Wainwright decreased their price objective on Erasca from $8.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, May 20th. The Goldman Sachs Group decreased their price objective on Erasca from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, May 28th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $6.00.
Check Out Our Latest Research Report on ERAS
Erasca Trading Up 2.4 %
Erasca (NASDAQ:ERAS – Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.02). On average, analysts forecast that Erasca, Inc. will post -0.77 earnings per share for the current fiscal year.
Insider Buying and Selling at Erasca
In other news, Director Alexander W. Casdin bought 80,000 shares of the stock in a transaction dated Tuesday, May 21st. The stock was bought at an average cost of $2.27 per share, with a total value of $181,600.00. Following the purchase, the director now owns 573,974 shares of the company’s stock, valued at $1,302,920.98. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 21.50% of the company’s stock.
Institutional Investors Weigh In On Erasca
Hedge funds and other institutional investors have recently made changes to their positions in the company. Aaron Wealth Advisors LLC acquired a new stake in shares of Erasca in the 4th quarter valued at $28,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Erasca in the 4th quarter valued at $35,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Erasca by 350.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,472 shares of the company’s stock valued at $37,000 after buying an additional 13,597 shares during the period. RPO LLC acquired a new stake in shares of Erasca during the fourth quarter worth $44,000. Finally, Edmonds Duncan Registered Investment Advisors LLC grew its stake in shares of Erasca by 41.2% during the second quarter. Edmonds Duncan Registered Investment Advisors LLC now owns 34,280 shares of the company’s stock worth $81,000 after purchasing an additional 10,000 shares during the period. 67.78% of the stock is owned by institutional investors and hedge funds.
Erasca Company Profile
Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.
Featured Stories
- Five stocks we like better than Erasca
- How to Use the MarketBeat Dividend Calculator
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Airline Stocks – Top Airline Stocks to Buy Now
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.